Company Analysis

Arcutis Biotherapeutics, Inc. (ARQT)

Nasdaq: ARQT · Pharmaceutical Preparations · Westlake Village, CA · filing with the SEC since 2019
Grade6.4
◀ Past 6.7● Present 6.8▶ Future 5.5
1 est.

Filings

258 filings since 2017 beside 609 insider forms · Large accelerated filer · read from EDGAR on Nov 13, 2026
Due nextLarge accelerated filer
10-K Annual report for the fiscal year ending Dec 31, 2026Large accelerated filers have 60 days after the fiscal year ends. by Mar 1, 2027
10-Q Quarterly report for the quarter ending Mar 31, 2027Large accelerated filers have 40 days after the quarter ends; quarter ends are taken to the month end. by May 10, 2027

A deadline is the latest date the SEC's rules allow for its filer category. It is not a forecast of the day the company files. Last time, the results release (8-K item 2.02) came 35 days after the quarter ended. The proxy statement was last filed Apr 21, 2026.

Filings a yearinsider forms included
91131189090148168131
20192020202120222023202420252026

2026 counts to Nov 13, 2026.

Officer or director change (8-K item 5.02): 7 times in the last 36 months, the newest Oct 28, 2026.SEC letters: 7 in the last 36 months, the newest Dec 2, 2025.
Insider forms 609

Insider forms (3, 4, 5 and 144) are counted each year but not listed here; the people and their trades are on the Ownership tab.

FiledFormWhat it is, in plain wordsPeriodAsk
Nov 10, 2026 SCHEDULE 13G Large holder notice
Nov 4, 2026 10-Q Quarterly report Sep 30, 2026
Nov 4, 2026 8-K items 2.02, 9.01 Results released · Current report
Nov 4, 2026 424B5 Shelf offering
Oct 28, 2026 8-K items 5.02, 7.01, 9.01 Officer or director change; Investor disclosure (Regulation FD) · Current report Oct 23, 2026
Oct 5, 2026 SCHEDULE 13G/A Large holder update, amended
Aug 14, 2026 SCHEDULE 13G Large holder notice
Aug 7, 2026 SCHEDULE 13G Large holder notice
Aug 5, 2026 10-Q Quarterly report Jun 30, 2026
Aug 5, 2026 8-K items 2.02, 5.02, 9.01 Results released; Officer or director change · Current report Jul 31, 2026
Jul 16, 2026 8-K items 5.02, 7.01, 9.01 Officer or director change; Investor disclosure (Regulation FD) · Current report Jul 15, 2026
Jun 9, 2026 8-K items 5.07, 8.01, 9.01 Shareholder vote; Other event · Current report Jun 5, 2026
May 12, 2026 SCHEDULE 13G Large holder notice
May 8, 2026 SCHEDULE 13G/A Large holder update, amended
May 6, 2026 10-Q Quarterly report Mar 31, 2026
May 6, 2026 8-K item 9.01 Financial statements and exhibits · Current report
May 6, 2026 SCHEDULE 13G/A Large holder update, amended
Apr 21, 2026 S-8 Employee stock plan registration
Apr 21, 2026 ARS Annual report to shareholders
Apr 21, 2026 DEFA14A Extra proxy material
Apr 21, 2026 DEF 14A Proxy statement
Mar 26, 2026 SCHEDULE 13G/A Large holder update, amended
Feb 25, 2026 S-8 Employee stock plan registration
Feb 25, 2026 S-3ASR Shelf registration
Feb 25, 2026 10-K Annual report Dec 31, 2025
Feb 25, 2026 8-K items 2.02, 9.01 Results released · Current report
Feb 13, 2026 SCHEDULE 13G/A Large holder update, amended
Feb 13, 2026 SCHEDULE 13G/A Large holder update, amended
Jan 30, 2026 SCHEDULE 13G/A Large holder update, amended
Dec 8, 2025 8-K items 5.02, 7.01, 9.01 Officer or director change; Investor disclosure (Regulation FD) · Current report Dec 3, 2025
Dec 2, 2025 UPLOAD SEC comment letter
Oct 28, 2025 10-Q Quarterly report Sep 30, 2025
Oct 28, 2025 8-K items 2.02, 9.01 Results released · Current report
Oct 10, 2025 CORRESP Reply to the SEC
Oct 6, 2025 SCHEDULE 13G/A Large holder update, amended
Sep 15, 2025 UPLOAD SEC comment letter
Aug 20, 2025 SCHEDULE 13D/A Activist holder update, amended
Aug 14, 2025 SCHEDULE 13G/A Large holder update, amended
Aug 6, 2025 10-Q Quarterly report Jun 30, 2025
Aug 6, 2025 8-K items 2.02, 9.01 Results released · Current report
40 of 258 shown

Every row opens the filing on EDGAR. The plain words are the site's own for each form and each 8-K item; the complete history, insider forms included, is on EDGAR.

SI Assistanton ARQT · research, not advice